Multiple cellular and pathway targets

Multiple cellular and pathway targets is a descriptive classification rather than a specific biological molecule or receptor. It is used in pharmacological contexts to describe drugs, such as multi-kinase inhibitors or broad-spectrum cytotoxic agents, that exert their therapeutic effects by interacting with a wide variety of molecular targets and signaling pathways simultaneously (Nature Reviews Drug Discovery, 2019). This polypharmacological approach is often intended to disrupt complex disease networks, such as those found in cancer, where inhibiting a single target might be bypassed by compensatory cellular mechanisms (PubMed, PMID: 22329230). For example, drugs like sorafenib are designed to inhibit multiple tyrosine kinases, including VEGFR and PDGFR, to provide a more comprehensive anti-tumor effect than a single-target agent (PubMed, PMID: 15460893). While this strategy can enhance clinical efficacy and reduce the likelihood of acquired resistance, it also presents significant challenges, including a higher risk of off-target toxicities and difficulty in identifying specific biomarkers for treatment response. In structured drug databases, this term often serves as a placeholder or a collective category for agents with complex, multi-faceted mechanisms of action that cannot be attributed to a single primary protein (DrugBank).

Other names

Multi-targetPolypharmacological targetsNon-specific targetsNetwork targets

Simultaneous modulation of multiple distinct molecular targets and signaling cascades to achieve a synergistic therapeutic effect.